Curcumin (Diferuloylmethane) Downregulates Expression of Cell Proliferation,

Antiapoptotic and Metastatic Gene Products Through Suppression of IkBa Kinase and

AKT Activation

Sita Aggarwal, Haruyo Ichikawa, Yasunari Takada, Santosh K. Sandur,

Shishir Shishodia and Bharat B. Aggarwal

Cytokine Research Laboratory, Department of Experimental Therapeutics,

The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

This work was supported by the Theodore N. Law Award Scientific Achievement Fund of The University of Texas M. D. Anderson Cancer Center (to Y. T. and S. S.) and by the Clayton Foundation for Research, U. S. Department of Defense Army Breast Cancer Research Program grant BC010610, National Cancer Institute PO1 grant CA91844 on lung chemoprevention, and National Cancer Institute P50 Head and Neck SPORE grant CA97007 (to B. B. A.), and the National Cancer Institute institutional support grant CA16672.

Running Title: Curcumin suppresses activation of IKK, AKT.

To whom correspondence should be addressed: Bharat B. Aggarwal, Department of

Experimental Therapeutics, Box 143, The University of Texas M. D. Anderson Cancer Center,

1515 Holcombe Blvd., Houston, TX 77030-4009. Tel.: 713-792-3503 ext. 6459; Fax: 713-794-

1613; E-mail: aggarwal@mdanderson.org.

The abbreviations used are: EMSA, electrophoretic mobility shift assay; EGFR,

epidermal growth factor receptor; HER, human epidermal growth factor receptor, IAP,

inhibitor-of-apoptosis protein; IkB, inhibitory subunit of NF-kB; FLICE, Fas associated

death domain protein-like interleukin-1β-converting enzyme inhibitory protein; FLIP,

FLICE-inhibitory protein; iNOS, inducible nitric oxide synthase; MMP, matrix

metalloproteinase; NF-κB, nuclear factor-κB; NIK, NF-κB-inducing kinase; PBS,

phosphate-buffered saline; SDS, sodium dodecyl sulfate; SEAP, secretory alkaline

phosphatase; VEGF, vascular endothelial growth factor, XIAP, X-chromosome-linked IAP.

Number of text pages: 34 Tables: 0 Figures: 7 References: 55

Number of words Abstract: 269 Introduction: 462 Discussion: 991

MOL 17400

Abstract

Curcumin (diferuloylmethane), an anti-inflammatory agent used in traditional medicine, has been shown to suppress cellular transformation, proliferation, invasion, angiogenesis, and metastasis through a mechanism not fully understood. Because several genes that mediate these processes are regulated by nuclear factor- κB (NF- κB), we have postulated that curcumin mediates its activity by modulating NF-KB activation. Indeed our laboratory has shown that curcumin can suppress NF- κ B activation induced by a wide variety of agents (Singh S, Aggarwal BB. J Biol Chem. 1995;270:24995-5000). In the present study, we investigated the mechanism by which curcumin manifests its effect on NF-KB and NFκB-regulated gene expression. Screening of 20 different analogues of curcumin showed that curcumin was the most potent analogue in suppressing the TNF-induced NF- κ B activation. Curcumin inhibited TNF-induced NF-kB-dependent reporter gene expression in a dose-dependent manner. Curcumin also suppressed NF-KB reporter activity induced by TNFR1, TNFR2, NIK, IKK, and the p65 subunit of NF-κB. Such TNF-induced NF-κBregulated gene products involved in cellular proliferation (COX-2, cyclin D1, c-myc), antiapoptosis (IAP1, IAP2, XIAP, Bcl2, Bcl-x_L, Bf1-1/A1, TRAF1, cFLIP) and metastasis (VEGF, MMP-9, ICAM-1) were also downregulated by curcumin. COX-2 promoter activity induced by TNF was abrogated by curcumin. We found that curcumin suppressed TNF-induced nuclear translocation of p65, which corresponded with the sequential suppression of $I\kappa B\alpha$ kinase activity, $I\kappa B\alpha$ phosphorylation, $I\kappa B\alpha$ degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acetylation. Curcumin also inhibited

MOL 17400

TNF-induced Akt activation and its association with IKK. Glutathione and dithiothreitol, reversed the effect of curcumin on TNF-induced NF- κ B activation. Overall, our results indicated that curcumin inhibits NF- κ B activation and NF- κ B–regulated gene expression through inhibition of IKK and AKT activation.

MOL 17400

Introduction

It is generally assumed that traditional medicines are safe and efficacious, given that they have been used for centuries. In spite of the widespread use of these medicines, however, research to definitively establish safety and efficacy of many of them is lacking. Between 1981-2002, almost 74% (48 out of 65) of all drugs approved for cancer were either natural products or based on natural products (typically, analogues or mimics) (Newman et al., 2003). The delineation of their mechanism of action may have an enormous influence on the development of new cancer therapies.

One of these traditional medicines, curcumin, is a component of the culinary spice turmeric, which is also often used in curry powder. Its active ingredient was first isolated in 1842 by Vogel. In 1910 Milobedzka determined that the structure was diferuloylmethane, and this compound was first synthesized in 1918 by Lampe and cocrystalized with 5 lipoxygenase in 2003 by Skrzypczak-Jankun (Skrzypczak-Jankun et al., 2000). Extensive research over the last 50 years has indicated that this polyphenol can both prevent and treat cancer. That curcumin can suppress tumor initiation, promotion, and metastasis has also been demonstrated (Aggarwal et al., 2003). The anticancer potential of curcumin stems from its ability to suppress proliferation of a wide variety of tumor cells, downregulate transcription factors; downregulate the expression of cyclooxygenase-2 (COX-2), lipoxygenase (LOX), inducible nitric oxide synthase (iNOS), matrix metalloproteiase-9 (MMP-9), uPA, TNF, chemokines, cell surface adhesion molecules, and cyclin D1; downregulate growth factor receptors (such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER2)); and inhibit the activity of c-Jun N-

terminal kinase, protein tyrosine kinases, and protein serine/threonine kinases (Aggarwal et al., 2003).

In several systems, curcumin has been described as a potent antioxidant and antiinflammatory agent. The compound has been found to be pharmacologically safe: Human clinical trials indicated no dose-limiting toxicity when administered at doses up to 10 g/day (Cheng et al., 2001). All of these studies suggest that curcumin has enormous potential in prevention and therapy of cancer. However, a better understanding of the mechanism would enhance the therapeutic potential of curcumin either alone or in combination with chemotherapy.

Over ten years ago our group showed that curcumin could suppress NF- κ B activation induced by TNF, phorbol ester, and H₂O₂ through suppression of I κ B α degradation (Singh and Aggarwal, 1995). How curcumin suppresses NF- κ B activation, is not fully understood. Because of numerous developments in our understanding of the pathway that leads to NF- κ B activation by TNF, we further revisited the mechanism by which curcumin modulates this pathway. From our results, we conclude that curcumin inhibits TNF-induced I κ B α kinase (IKK) and AKT activation, which blocks phosphorylation of I κ B α and p65, leading to suppression of events required for NF- κ B gene expression, specifically degradation of I κ B α and nuclear translocation of p65.

MOL 17400

Materials and Methods

Reagents—Curcumin (diferuloylmethane), 4-hydroxybenzophenone,4hydroxyvalerophenone, cinnamic acid, caffeic acid (3,4-dihydroxycinnamic acid), 3,4methylenedioxy cinnamic acid, 3,4-dimethoxycinnamic acid, 4-hydroxyphenyl pyruvic acid, 3,4-dihydroxyhydrocinnamic acid, 4-hydroxycinnamic acid, 2-hydroxycinnamic acid, 3-hydroxycinnamic acid, 4-hydroxyphenethyl alcohol, eugenol (4-allyl-2methoxyphenol)(Sigma-Aldrich, St. Louis, MO), 4-hydroxybenzylacetone, 1,5-Bis(4dimethylaminophenyl)-1,4-pentadien-3-one, 4-(p-hydroxyphenyl)-3-butein-2-one, 6hydroxydibenzoylmethane, (Frinton Laboratories Inc., Lancaster, NH), 4-(4-hydroxy-3methoxyphenyl) acetone (KKK Laboratories, OH), and 4-(3, 4-methylenedioxyphenyl)-2butanone (Chemical Dynamics Corp., N.J) were kindly supplied by Rajinder Verma of Baylor college of Medicine, Houston, TX. A 20 mM solution of curcumin and its analogues was prepared with dimethyl sulfoxide, stored as small aliquots at -20 °C, and that dimethyl sulfoxide and diluted as needed in cell culture medium. Bacteria-derived recombinant human TNF, purified to homogeneity with a specific activity of 5 x 10^7 U/mg, was kindly provided by Genentech (South San Francisco, CA). Penicillin, streptomycin, RPMI 1640 medium, and fetal bovine serum (FBS) were obtained from Invitrogen (Grand Island, NY). Glutathione reduced form and Anti-β-actin antibody were obtained from Aldrich-Sigma (St. Louis, MO). Antibodies against p65, p50, IKBa, Akt, cyclin D1, and MMP-9, anti-c-myc, antiinhibitor-of-apoptosis protein-1 (anti-IAP1), anti-IAP2, anti-Bcl-2, anti-Bcl-xL, and anti-Bfl-1/A1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-COX-2

MOL 17400

and anti-X-chromosome-linked IAP) anti-XIAP antibodies were obtained from BD Biosciences (San Diego, CA). Phospho-specific anti-I κ B α (Ser32), phospho-specific antip65 (Ser536), phospho-specific anti-Akt, and anti-acetyl-lysine antibodies were purchased from Cell Signaling (Beverly, MA). Anti-IKK- α , anti-IKK- β , and anti-Fas associated death domain protein-like interleukin-1 β -converting enzyme inhibitory protein (anti-FLIP) antibodies were kindly provided by Imgenex (San Diego, CA).

Cell Lines—U937 (human myeloid leukemia) and A293 (human embryonic kidney) cells were obtained from American Type Culture Collection (Bethesda, MD). U937 cells were cultured in Iscove's modified Dulbecco's medium with 15% FBS, and A293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. All culture media were also supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. EMSA—To assess NF- κ B activation, we performed electrophoretic mobility shift assay (EMSA) as described previously (Chaturvedi et al., 2000). Briefly, nuclear extracts prepared from TNF-treated cells were incubated with ³²P-end-labeled 45-mer doublestranded NF- κ B oligonucleotide (15 μ g of protein with 16 fmol of DNA) from the human immunodeficiency virus long terminal repeat 5'-TTGTTACAA GGGACTTTC CGCTG GGGACTTTC CAGGGAGGCGTGG-3' (boldface indicates NF-κB binding sites) for 30 min at 37 °C, and the DNA-protein complex formed was separated from free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5'-TTGTTACAA CTCACTTTC CGCTG CTCACTTTC CAGGGAGGCGTGG-3', was used to examine the specificity of binding of NF- κ B to the

MOL 17400

DNA. The specificity of binding was also examined by competition with the unlabeled oligonucleotide. For supershift assays, nuclear extracts prepared from TNF-treated cells were incubated with antibodies against the p50 or p65 subunit of NF-κB for 15 min at 37 °C before the complex was analyzed by EMSA. Anti-cyclin D1 antibody and preimmune serum (PIS) were included as negative controls. The dried gels were visualized with a PhosphorImager (Amersham, Piscataway, NJ), and bands were quantitated using ImageQuant software (Amersham).

Western Blot Analysis—To determine the levels of protein expression in the cytoplasm or nucleus, we prepared extracts (Takada et al., 2003) and fractionated them by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, the proteins were electrotransferred to nitrocellulose membranes, blotted with each antibody, and detected with enhanced chemiluminescent reagent (Amersham). The intensities of the bands were quantitated using NIH Image (National Institutes of Health, Bethesda, MD).

Kinase Assay—To determine the effect of curcumin on TNF-induced IKK activation, we performed an immunocomplex kinase assay as described previously (Manna et al., 2000). Briefly, the IKK complex from whole-cell extracts was precipitated with antibody against IKK- α followed by treatment with protein A/G-Sepharose beads (Pierce, Rockford, IL). After 2 h of incubation, the beads were washed with lysis buffer and assayed in a kinase assay mixture containing 50 mM HEPES, pH 7.4, 20 mM MgCl2, 2 mM dithiothreitol, 20 mCi [γ -³²P]ATP, 10 mM unlabeled ATP, and 2 µg of substrate glutathione S-transferase (GST)–IkB α (amino acids 1–54). After incubation at 30 °C for 30 min, the reaction was

terminated by boiling with SDS sample buffer for 5 min. Finally, the protein was resolved on 10 % SDS-PAGE, the gel was dried, and the radioactive bands were visualized with a PhosphorImager. To determine the total amounts of IKK- α and IKK- β in each sample, 50 µg of the whole-cell protein was resolved on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and blotted with anti-IKK- α or anti-IKK- β antibody. NF-KB-dependent Reporter Gene Expression Assay-The effect of curcumin on TNF-, TNFR1-, TNFR2-, NIK-, IKK-, and p65-induced NF-KB-dependent reporter gene transcription was analyzed by secretory alkaline phosphatase (SEAP) assay as previously described. Briefly, A293 cells were plated in 12-well plates (2 x 10⁵ cells/well) and transiently transfected by Fugene 6 (Roche Molecular Biochemicals, Mannheim, Germany). To examine TNF-induced reporter gene expression, we transfected the cells with 0.2 µg of the SEAP expression plasmid for 24 h. Thereafter we treated the cells for 24 h with 10µM curcumin or its analogues and then stimulated them with 1 nM TNF for a further 24 h. To examine the expression of various gene-induced reporter genes, we transfected cells with 0.2 µg of reporter gene plasmid with each 0.5 µg of expressing plasmid for 24 h and then treated the cells with curcumin for 48 h. The cell culture medium was harvested and analyzed for SEAP activity according to the protocol essentially as described by the manufacturer (Clontech, Palo Alto, CA) using a 96-well fluorescence plate reader (Fluoroscan II; Labsystems, Chicago, IL) with excitation set at 360 nm and emission at 460 nm.

p65 Acetylation—To determine the effect of curcumin on TNF-induced acetylation of p65, cells (5 x 10^6) were treated with TNF, curcumin or combination, washed with ice-cold

MOL 17400

phosphate-buffered saline (PBS), and lysed in a buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EGTA, 2 mM NaF, 10% glycerol, 0.2% Triton X-100, 0.2 mM sodium orthovanadate, 2 μ g/ml aprotinin, and 2 μ g/ml leupeptin . The resulting whole-cell lysates were incubated with anti-p65 antibody for 2 h and precipitated using protein A/G-Sepharose beads. After 1 h of incubation, immunocomplexes were washed with lysis buffer, boiled with SDS sample buffer for 5 min, resolved on SDS-PAGE, and subjected to Western blot analysis with anti-acetyl-Lysine antibody.

*Immunocytochemical Analysis of NF-*κ*B p65 Localization*—The effect of curcumin on the nuclear translocation of p65 was examined by immunocytochemistry as previously described (Takada et al., 2003). Briefly, treated cells were plated on a poly-L-Lysine—coated glass slide by centrifugation using a Cytospin 4 (Thermoshendon, Pittsburg, PA), air dried, and fixed with 4% paraformaldehyde following permeabilization with 0.2% Triton X-100. After being washed in PBS, slides were blocked with 5% normal goat serum for 1 h and then incubated with rabbit polyclonal anti-human p65 antibody at a 1:200 dilution. After incubation for 12 h at 4 °C, the slides were washed, incubated with Alexa Fluor 594-conjugated goat anti-rabbit immunoglobulin G at a 1:200 dilution for 1 h, and counterstained for nuclei with 50 ng/ml Hoechst 33342 dye for 5 min. Stained slides were mounted with mounting medium purchased from Sigma Chemical and analyzed under a fluorescence microscope (Labophot-2; Nikon, Tokyo, Japan). Pictures were captured using a Photometrics Coolsnap CF color camera (Nikon, Lewisville, TX) and MetaMorph version 4.6.5 software (Universal Imaging, Downingtown, PA).

MOL 17400

Invasion assay—Invasion through the extracellular matrix is a crucial step in tumor metastasis. We used Matrigel basement membrane matrix extracted from the Englebreth-Holm-Swarm mouse tumor as a reconstituted basement membrane for in vitro invasion assays. The BD BioCoat tumor invasion system we used has a chamber with a light-tight polyethelyene terephlate membrane with 8- μ m pores coated with a reconstituted basement membrane gel (BD Biosciences). We resuspended 2.5 x 10⁴ H1299 cells in serum-free medium and seeded the suspension into the upper wells. After incubation overnight, cells were incubated with different concentrations of curcumin for 2 h and then incubated with 1nM TNF for a further 24 h in the presence of 1% FBS. The cells that passed through the Matrigel were labeled with 4 μ g/ml Calcein AM (Molecular probe) in PBS for 30 min at 37 °C and subjected to scan fluorescence by a Vector 3 luminometer (Perkin Elmer Life & Analytical Sciences, Boston, MA).

MOL 17400

Results

Curcumin has a more pronounced effect than any of its analogues on TNF-induced NF- κB activation—Besides curcumin, several analogues with similar structures have been identified from natural sources (see Fig. 1A). Whether these analogues also suppress TNFinduced NF- κB activation was examined by EMSA. Results in Fig. 1B show that TNF activated NF- κB almost by five-fold and all the analogues of curcumin suppressed NF- κB activation under identical conditions. However, none of the analogues was as effective as native curcumin.

We also examined the effect of curcumin and its analogues on TNF-induced NF- κ B-dependent reporter gene transcription. Results in Fig. 1C indicate that TNF stimulated the NF- κ B reporter activity by almost 18-fold and curcumin suppressed the activity. None of the curcumin analogues were as potent as curcumin. Thus these results indicate that, among all the analogues, curcumin is the most potent inhibitor of NF- κ B activation.

Curcumin does not directly inhibit binding of NF- κ B to DNA: How curcumin inhibits TNF-induced NF- κ B activation was investigated in detail. To determine whether curcumin directly modifies the binding of the NF- κ B complex to DNA, we incubated nuclear extracts from TNF-stimulated cells with curcumin and then analyzed DNA-binding activity by using EMSA. Curcumin did not modify the DNA-binding ability of the NF- κ B complex even at 300 μ M concentration (Fig. 1D). We concluded that curcumin inhibits NF- κ B activation indirectly.

MOL 17400

Curcumin suppresses TNF-induced NF- κ B-dependent reporter gene expression in a dosedependent manner—DNA binding does not always correspond with NF- κ B-dependent gene transcription (Nasuhara et al., 1999). To determine the effect of curcumin on TNFinduced NF- κ B-dependent reporter gene expression, we transiently transfected cells with the NF- κ B-regulated SEAP reporter construct, incubated them with different concentrations of curcumin, and then stimulated them with TNF. We found that TNF induced NF- κ B reporter activity and that this activity was inhibited by curcumin in a dosedependent manner (Fig. 2A).

Curcumin suppresses the NF- κ B-dependent reporter gene expression pathway activated by TNF—TNF-induced NF- κ B activation is mediated through the sequential interaction of the TNF receptor with NF- κ B-inducing kinase (NIK), and IKK, resulting in phosphorylation of I κ B α (Hsu et al., 1996; Simeonidis et al., 1999). To determine the effect of curcumin on the NF- κ B-dependent reporter gene expression pathway activated by TNF, we transiently transfected cells with the NF- κ B-regulated SEAP reporter construct, along with TNFR1-, TNFR2-, NIK-, IKK- and p65-expressing plasmids, and then treated them with curcumin and examined them for NF- κ B-dependent SEAP expression. Cells transfected with TNFR1, TNFR2-, NIK, IKK, and p65 plasmids showed NF- κ B-regulated reporter gene expression; curcumin suppressed TNFR 1-, TNFR2-, NIK- IKK- and p65-induced NF- κ B reporter gene expression (Fig. 2B).

Curcumin inhibits TNF-induced COX-2 promoter activity. TNF induces expression of COX-2, which has NF-κB-binding sites in its promoter (Shishodia and Aggarwal, 2004).

Because downregulation of NF- κ B by curcumin suppressed the expression of NF- κ Bregulated gene products, we examined the effect of curcumin on TNF-induced COX-2 promoter activity by using a COX-2 promoter-luciferase reporter plasmid. We found that TNF-induced COX-2 promoter activity was suppressed by curcumin in a dose-dependent manner (Fig. 2C).

Curcumin represses the TNF-induced NF- κ B-dependent gene products involved in cell proliferation. Cyclin D1 is overexpressed in a wide variety of tumors and mediates the progress of cells from the G1 to the S phase (Polsky and Cordon-Cardo, 2003). Similarily, COX-2 is overexpressed in tumor cells and mediates proliferation (Chun and Surh, 2004). The role of c-myc in proliferation of tumor is well established (Schmidt, 2004). The expression of all three genes is regulated by NF- κ B (Esteve et al., 2002; Guttridge et al., 1999; Yamamoto et al., 1995). We found that curcumin also blocked expression of these genes (Fig. 2D). These results further strengthen our postulate that curcumin blocks TNFinduced NF- κ B-regulated gene products.

Curcumin represses TNF-induced NF-κB-dependent anti-apoptotic gene products. NF-κB regulates the expression of the anti-apoptotic proteins inhibitor-of-apoptosis protein 1/2 (IAP1/2), X-chromosome-linked inhibitor of apoptosis protein XIAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP(Catz and Johnson, 2001; Catz and Johnson, 2003; Chu et al., 1997; Grumont et al., 1999; Kreuz et al., 2001; Stehlik et al., 1998; Tamatani et al., 1999; You et al., 1997; Zhou et al., 2004; Zhu et al., 2001; Zong et al., 1999), so we examined whether curcumin can modulate the expression of these anti-apoptotic gene products induced by

TNF. As shown in Fig. 2E, curcumin blocked the expression of these TNF-induced antiapoptotic proteins as well.

Curcumin represses the TNF-induced NF- κ B-dependent gene products involved in angiogenesis and metastasis. The roles of VEGF, MMP-9, and ICAM-1 in angiogenesis and metastasis of tumors are well established. All three gene products are also regulated by NF- κ B, (Gorgoulis et al., 2003; Jung et al., 2003; Sanceau et al., 2002) so we investigated curcumin's effect on this regulation. Western blot analysis showed that curcumin blocked TNF-induced VEGF, ICAM-1 and MMP-9 protein expression in a time-dependent manner (Fig. 2F). These results suggest that curcumin plays a role in suppressing angiogenesis and metastasis.

Curcumin suppresses TNF-induced invasion activity. Matrix metalloproteinases and cyclooxygenases, and adhesion molecules that are regulated by NF-κB have been shown to mediate tumor invasion (Liotta et al., 1982), and TNF can induce expression of genes involved in tumor metastasis (van de Stolpe et al., 1994). Whether curcumin modulates TNF-induced invasion activity in vitro was examined. For this study, we used H1299 cells seeded in the top chamber of a Matrigel invasion chamber in the absence of serum. Cells were incubated with different concentration of curcumin for 2h and then, incubated with TNF for 24 h. As shown in Fig. 2G, TNF induced cell-invasion activity and curcumin suppressed it.

Curcumin inhibits TNF-induced NF-\kappa B DNA binding in a dose- and time-dependent manner—To determine whether suppression of NF- κB DNA-binding by curcumin is dose dependent, we treated cells with different concentrations of curcumin and then with TNF.

MOL 17400

EMSA showed that curcumin by itself did not activate NF- κ B, but TNF-induced NF- κ B activation was inhibited by curcumin in a dose-dependent manner (Fig. 3A). We also investigated the length of incubation required for curcumin to suppress TNF-induced NF- κ B activation. Cells were incubated with curcumin for up to 2 h and then exposed to TNF. EMSA results showed that TNF-induced NF- κ B activation was completely abolished at 2 h (Fig. 3B). Under these conditions, cells were fully viable (data not shown).

Because various combinations of Rel/NF- κ B protein constitute active NF- κ B heterodimers that bind specific DNA sequences (Aggarwal, 2004), we decided to show that the band visualized by EMSA in TNF-treated cells was indeed NF- κ B. When nuclear extracts from TNF-stimulated cells were incubated with antibodies against the p50 (NF- κ B1) or p65 (RelA) subunit of NF- κ B, the band was shifted to a higher molecular mass (Fig. 3C), suggesting that the TNF-activated complex consisted of both p50 and p65 subunits. Preimmune serum had any effect. Excess (100-fold) unlabeled NF- κ B caused complete disappearance of the band, but a mutant oligonucleotide of NF- κ B did not affect NF- κ B-binding activity.

Curcumin inhibits TNF-dependent I \kappa \beta \alpha degradation— The translocation of NF- κB to the nucleus is preceded by the proteolytic degradation of I $\kappa \beta \alpha$ (Aggarwal, 2004). To determine whether the inhibitory activity of curcumin was due to inhibition of I $\kappa \beta \alpha$ degradation, we treated cells with curcumin and then with TNF and examined them for I $\kappa \beta \alpha$ degradation. Our results indicated that curcumin inhibited TNF-induced I $\kappa \beta \alpha$ degradation (Fig. 4A).

Curcumin inhibits TNF-dependent $I\kappa B\alpha$ phosphorylation— We next determined whether curcumin's inhibition of TNF-induced $I\kappa B\alpha$ degradation was due to inhibition of $I\kappa B\alpha$ phosphorylation. Western blot analysis using an antibody that recognizes the serinephosphorylated form of $I\kappa B\alpha$ showed that TNF-induced $I\kappa B\alpha$ phosphorylation was almost completely suppressed by curcumin (Fig. 4B).

Curcumin inhibits TNF-induced IKK activation—IKK is required for TNF-induced phosphorylation of IκBα (Aggarwal, 2004). Because curcumin inhibited the phosphorylation of IκBα in our study, we assessed whether it directly affects TNF-induced IKK activation. Results from the immunocomplex kinase assay showed that curcumin suppressed TNF-induced activation of IKK in a dose- (Fig. 4D) and time-dependent (Fig. 4C) manner. Neither TNF nor curcumin affected the expression of IKK.

Curcumin directly inhibits IKK activity—To evaluate whether curcumin suppresses the IKK activity directly by binding to the IKK protein or by suppressing the activation of IKK, we immunoprecipitated the IKK from whole-cell extracts from TNF-treated cells, then incubated with various concentrations of curcumin, and then performed the immunecomplex kinase assay. The results showed that curcumin directly suppressed the activity of IKK (Fig. 4E).

Curcumin Inhibits TNF-induced Nuclear Translocation of p65 — We also determined the effect of curcumin on TNF-induced nuclear translocation of p65. Curcumin almost completely suppressed the TNF-induced nuclear translocation of p65 as shown by western blot analysis (Fig. 5A) and by immunocytochemistry (Fig. 5B). Curcumin also suppressed the TNF-induced phosphorylation of p65 (Fig. 5C). This phosphorylation of p65 is required

for its transcriptional activity and subsequent translocation to the nucleus (Zhong et al., 1998).

Because the acetylation of p65 plays a key role in activation of NF-κB transcriptional activity (Kiernan et al., 2003), we examined the effect of curcumin on the induction of p65 acetylation by TNF. We treated cells with curcumin and then with TNF, prepared whole-cell extracts, and immunoprecipitated them with anti-p65 antibody. Western blot analysis using anti-acetyl-lysine antibody showed that curcumin suppressed TNF-induced acetylation of p65 (Fig. 6A).

Curcumin Inhibits TNF-induced Akt Activation—It has been shown that Akt can activate IKK (Ozes et al., 1999) and induce p65 phosphorylation (Sizemore et al., 1999). Thus it is possible that curcumin suppresses TNF-induced Akt activation. Western blot analysis using anti-phosphospecific-Akt antibody showed that curcumin suppressed TNF-induced Akt activation (Fig. 6B).

Whether curcumin affects the association of Akt with IKK was also examined. We prepared the whole-cell extracts from TNF-treated cells, immunoprecipitated them with anti-IKK α antibody, and performed Western blot analysis using anti-Akt antibody. Curcumin suppressed the TNF-induced association between IKK and Akt (data not shown). *Reducing agents reverse curcumin-mediated suppression of TNF-induced NF-KB activation*- Curcumin is characterized by the presence of two olefinic moieties conjugated to ketone groups, which implies that curcumin may act as Michael acceptor. Whether curcumin mediates its effects by altering the redox status of the cells, was investigated. To determine this, cells were exposed to curcumin along with dithiothreitol (DTT) for 4 h and

MOL 17400

then examined TNF-induced NF- κ B activation. We found that DTT had no effect on TNFinduced NF- κ B activation but it significantly reversed the inhibitory effects of curcumin on NF- κ B activation (Fig. 7A). Besides DTT, we also examined the effect glutathione on curcumin's ability to suppress TNF-induced NF- κ B activation. In agreement with DTT results, we found once again that glutathione reversed the effect of curcumin (Fig. 7B). These results clearly suggest that curcumin mediates its effects through modulation of redox status of the cell.

MOL 17400

Discussion

The goal of the current study was to investigate the mechanism by which curcumin manifests its suppressive effects on NF- κ B activation. Among 20 different analogues examined, curcumin was found to be the most potent in suppressing TNF-induced NF- κ B activation. Curcumin suppressed TNF-induced NF- κ B–dependent reporter gene expression and that induced by TNFR1, TNFR2, NIK, IKK and the p65 subunit of NF- κ B. NF- κ B– regulated gene products were also downregulated by curcumin. TNF-induced nuclear translocation of p65, which corresponded with the sequential suppression of I κ B α kinase activity, I κ B α phosphorylation, I κ B α degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acetylation, were all downregulated by curcumin. This polyphenol also inhibited TNF-induced Akt activation and its association with IKK.

Previous work from our laboratory and others have shown that curcumin inhibits NF-κB activation induced by various agents including TNF, H₂O₂, PMA, hypoxia, cigarette smoke (Anto et al., 2002; Plummer et al., 1999). In response to most of these stimuli, NFκB activation proceeds sequentially through activation of IKK, phosphorylation at serines 32 and 36 of IκBα, ubiquitination at lysines 21 and 22 of IκBα, and finally degradation of IKBα and the release of NF-κB (Aggarwal, 2004). Our study indicates that curcumin inhibits NF-κB activation by suppressing IKK activation, so how curcumin inhibits IKK activation was also examined. Akt has been shown to associate with IKK and activate IKK (Ozes et al., 1999). We demonstrated that curcumin suppressed TNF-induced Akt activation as well as Akt-IKK association. These results thus indicate that curcumin may

inhibit IKK activation through suppression of Akt activation. Our results also, however, suggest that curcumin can directly inhibit the activity of IKK.

Whether curcumin inhibits NF-KB activation directly or through inhibition of IKK and AKT, is not clear. We found that the suppression of NF-KB activation by curcumin could be reversed by reducing agents, thus suggesting results that curcumin alters the redox status of the cells. A redox-sensitive cysteine residues have been identified in both p65 (Cysteine residue 38; (Garcia-Pineres et al., 2001)) and in IKK-β (Cysteine residue 179; (Kapahi et al., 2000)). It is possible that curcumin mediates its effects by oxidizing the critical cysteine residue present in p65 or IKK- β or both. Recently ethyl pyruvate was found to inhibit LPS-induced NF-kB activation by directly targeting p65 (Han et al., 2005). Furthermore, similar to curcumin, the suppression of LPS-induced NF-kB activation by ethyl pyruvate was found to be reversible by glutathione (Song et al., 2004). In agreement with these observations, Fang et al. showed that curcumin can irreversibly modify the thioredoxin reductase by causing the alkylation of Cys (496) and Sec (497) present in the catalytically active site of the enzyme (Fang et al., 2005). Similarly, critical cysteine residues that are modified by the inducers have also been identified in Keap1, a component of the transcription factor Nrf2, that regulates phase 2 genes (Wakabayashi et al., 2004).

TNF activates NF- κ B through sequential recruitment of TNFR1, TNFR2, NIK, and IKK (Hsu et al., 1996). We found that NF- κ B activation by all these plasmids was suppressed by curcumin. Our results are in agreement with a previous report that curcumin can inhibit NIK and IKK-induced NF- κ B reporter gene transcription (Plummer et al.,

1999). While DN-NIK inhibits TNF-induced NF- κ B activation, gene-deletion studies have indicated that NIK is not required for TNF-induced NF- κ B activation (Yin et al., 2001).

We found that curcumin also suppressed the phosphorylation of p65. Both IKK and AKT have been implicated in the phosphorylation of p65 (Sizemore et al., 2002; Sizemore et al., 1999). Thus curcumin could suppress p65 phosphorylation by inhibiting both AKT and IKK activation. We found that p65-induced NF-κB reporter activity was also suppressed by curcumin. Whether this suppression is also mediated through inhibition of phosphorylation or modification of a critical residue of p65 by curcumin is not clear. The phosphorylation of p65 has been shown to be needed for its transcriptional activity (Zhong et al., 1998). We also found that curcumin had no direct effect on the binding of p50-p65 to the DNA even at 300 μM concentration. These results contradict with a previous report indicating that curcumin induces the chemical modification of p65 at similar doses such that it can no longer bind to the DNA (Brennan and O'Neill, 1998).

We showed that curcumin downregulated the expression of NF-κB–regulated gene products involved in cellular proliferation (COX-2, cyclin D1, c-myc), antiapoptosis (IAP1, IAP2, XIAP, Bcl2, Bcl-xL, Bf1-1/A1, TRAF1, cFLIP) and metastasis (VEGF, MMP-9, ICAM-1). Cyclin D1, which is overexpressed in a variety of tumors (Mukhopadhyay et al., 2002), is regulated by NF-κB (Guttridge et al., 1999) and is required for cells to advance from the G1 phase to the S phase of the cell cycle (Weinstein, 2000). That curcumin downregulates cyclin D1 expression may explain the results from earlier reports indicating that this agent induces G1/S arrest (Anto et al., 2003; Schnaeker et al., 2004). It also may explain the antiproliferative effects of curcumin..

MOL 17400

Our finding that curcumin inhibited the tumor cell invasion through downregulation of the expression of NF-κB–regulated gene products involved in cell invasion (e.g., MMP-9). The dowregulation of VEGF as shown here could explain the antimetastatic activities of curcumin (Gasparini et al., 2003). COX-2 has been implicated in carcinogenic processes, and its overexpression by malignant cells has been shown to enhance cellular invasion, induce angiogenesis, regulate antiapoptotic cellular defenses, and augment immunologic resistance through production of prostaglandin E2 (Shiraga et al., 2002). MMP-9 plays a crucial role in tumor invasion and angiogenesis by mediating degradation of the extracellular matrix, and inhibition of MMP activity has been shown to suppress lung metastasis (Garg and Aggarwal, 2002).

Several chemokines, interleukins, and hematopoietic growth factors are regulated by NF- κ B activation (Gao et al., 2004). The immunomodulatory effects of curcumin (Chaturvedi et al., 2000) may also be mediated through the regulation of these cytokines. Overall, our results demonstrate that curcumin downregulates NF- κ B-regulated gene products involved in proliferation, cell survival, invasion, angiogenesis, metastasis, and inflammation through downregulation of IKK and AKT.

Acknowledgment: We thank Mr. Walter Pagel for carefully proofreading the manuscript and providing valuable comments. Dr. Takada and Dr. Shishodia are Odyssey Program Special Fellow at the University of Texas M. D. Anderson Cancer Center. Dr. Aggarwal is a Ransom Horne, Jr., Professor of Cancer Research at the University of Texas M. D. Anderson Cancer Center.

MOL 17400

References

Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-8.

- Aggarwal BB, Kumar A and Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res* **23**:363-98.
- Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG and Aggarwal BB (2002) Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. *Carcinogenesis* 23:1511-8.
- Anto RJ, Venkatraman M and Karunagaran D (2003) Inhibition of NF-kappaB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. *J Biol Chem* **278**:25490-8.
- Brennan P and O'Neill LA (1998) Inhibition of nuclear factor kappaB by direct modification in whole cells--mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. *Biochem Pharmacol* **55**:965-73.
- Catz SD and Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. *Oncogene* **20**:7342-51.
- Catz SD and Johnson JL (2003) BCL-2 in prostate cancer: a minireview. *Apoptosis* **8**:29-37.
- Chaturvedi MM, Mukhopadhyay A and Aggarwal BB (2000) Assay for redox-sensitive transcription factor. *Methods Enzymol* **319**:585-602.
- Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 21:2895-900.
- Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH and Ballard DW (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. *Proc Natl Acad Sci U S A* **94**:10057-62.

- Chun KS and Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. *Biochem Pharmacol* **68**:1089-100.
- Esteve PO, Robledo O, Potworowski EF and St-Pierre Y (2002) Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway. *Biochem Biophys Res Commun* **296**:864-9.
- Fang J, Lu J and Holmgren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. *J Biol Chem* 280:25284-90.
- Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, Chapman RA, Dulchavsky SA and Gautam SC (2004) Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. *Biochem Pharmacol* 68:51-61.
- Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL and Merfort I (2001) Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. *J Biol Chem* 276:39713-20.
- Garg A and Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. *Leukemia* **16**:1053-68.
- Gasparini G, Longo R, Sarmiento R and Morabito A (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? *Lancet Oncol* **4**:605-15.
- Gorgoulis VG, Zacharatos P, Kotsinas A, Kletsas D, Mariatos G, Zoumpourlis V, Ryan KM, Kittas C and Papavassiliou AG (2003) p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. *Embo J* **22**:1567-78.
- Grumont RJ, Rourke IJ and Gerondakis S (1999) Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. *Genes Dev* **13**:400-11.
- Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS, Jr. (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol* **19**:5785-99.

- Han Y, Englert JA, Yang R, Delude RL and Fink MP (2005) Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. *J Pharmacol Exp Ther* **312**:1097-105.
- Hsu H, Shu HB, Pan MG and Goeddel DV (1996) TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell* 84:299-308.
- Jung YJ, Isaacs JS, Lee S, Trepel J and Neckers L (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. *Faseb J* 17:2115-7.
- Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY and Karin M (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275:36062-6.
- Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S and Benkirane M (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. *J Biol Chem* 278:2758-66.
- Kreuz S, Siegmund D, Scheurich P and Wajant H (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. *Mol Cell Biol* 21:3964-73.
- Liotta LA, Thorgeirsson UP and Garbisa S (1982) Role of collagenases in tumor cell invasion. *Cancer Metastasis Rev* 1:277-88.
- Manna SK, Mukhopadhyay A and Aggarwal BB (2000) IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. *J Immunol* 165:4927-34.
- Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M and Aggarwal BB (2002) Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. *Oncogene* **21**:8852-61.
- Nasuhara Y, Adcock IM, Catley M, Barnes PJ and Newton R (1999) Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor

MOL 17400

necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. *J Biol Chem* **274**:19965-72.

- Newman DJ, Cragg GM and Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. *J Nat Prod* **66**:1022-37.
- Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB (1999) NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature* **401**:82-5.
- Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18:6013-20.

Polsky D and Cordon-Cardo C (2003) Oncogenes in melanoma. Oncogene 22:3087-91.

- Sanceau J, Boyd DD, Seiki M and Bauvois B (2002) Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 277:35766-75.
- Schmidt EV (2004) The role of c-myc in regulation of translation initiation. *Oncogene* **23**:3217-21.
- Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M and Schneider SW (2004) Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. *Cancer Res* 64:8924-31.
- Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H and Sone S (2002) Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. *Cancer Res* 62:5967-73.
- Shishodia S and Aggarwal BB (2004) Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. *J Biol Chem* 279:47148-58.

- Simeonidis S, Stauber D, Chen G, Hendrickson WA and Thanos D (1999) Mechanisms by which IkappaB proteins control NF-kappaB activity. *Proc Natl Acad Sci U S A* **96**:49-54.
- Singh S and Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. *J Biol Chem* **270**:24995-5000.
- Sizemore N, Lerner N, Dombrowski N, Sakurai H and Stark GR (2002) Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. *J Biol Chem* 277:3863-9.
- Sizemore N, Leung S and Stark GR (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. *Mol Cell Biol* 19:4798-805.
- Skrzypczak-Jankun E, McCabe NP, Selman SH and Jankun J (2000) Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence. *Int J Mol Med* 6:521-6.
- Song M, Kellum JA, Kaldas H and Fink MP (2004) Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. *J Pharmacol Exp Ther* 308:307-16.
- Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR and Lipp J (1998) Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. *J Exp Med* 188:211-6.
- Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S and Aggarwal BB (2003) Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. *J Biol Chem* 278:24233-41.

- Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T and Tohyama M (1999) Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. *J Biol Chem* 274:8531-8.
- van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JA, Johnson JP and van der Saag PT (1994) 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. *J Biol Chem* **269**:6185-92.
- Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW and Talalay P (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. *Proc Natl Acad Sci U S A* 101:2040-5.
- Weinstein IB (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis* 21:857-64.
- Yamamoto K, Arakawa T, Ueda N and Yamamoto S (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. *J Biol Chem* 270:31315-20.
- Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV and Schreiber RD (2001) Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. *Science* 291:2162-5.
- You M, Ku PT, Hrdlickova R and Bose HR, Jr. (1997) ch-IAP1, a member of the inhibitorof-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. *Mol Cell Biol* **17**:7328-41.
- Zhong H, Voll RE and Ghosh S (1998) Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. *Mol Cell* **1**:661-71.

- Zhou J, Callapina M, Goodall GJ and Brune B (2004) Functional integrity of nuclear factor kappaB, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha. *Cancer Res* 64:9041-8.
- Zhu L, Fukuda S, Cordis G, Das DK and Maulik N (2001) Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. *FEBS Lett* **508**:369-74.
- Zong WX, Edelstein LC, Chen C, Bash J and Gelinas C (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. *Genes Dev* **13**:382-7.

MOL 17400

Figure Legends

Fig. 1. (A) Structure of various analogues of curcumin: 1) Curcumin (diferuloylmethane), (2) 6-Hydroxydibenzoylmethane, (3) Caffeic acid (3,4dihydroxycinnamic acid), (4) 3,4-Methylenedioxy cinnamic acid, (5) 3,4-Dimethoxy cinnamic acid, (6) Cinnamic acid, (7) Zingerone (4-(4-Hydroxy-3-methoxyphenyl) acetone) (8) 4-(3, 4-Methylenedioxyphenyl)-2-butanone, (9) 4-(p-hydroxyphenyl)-3-butein [buten on fig]-2-one, (10) 4'-Hydroxyvalerophenone, (11) 4-Hydroxybenzylacetone, (12) 4-Hydroxybenzophenone, (13) 1,5-Bis(4-dimethylaminophenyl)-1,4-pentadien-3-one, (14) 4-Hydroxyphenethyl alcohol [I can't find this on the fig], (15) 4-Hydroxyphenyl pyruvic acid, (16) 3.4-dihydroxyhydrocinnamic acid, (17) 2-Hydroxycinnamic acid, (18) 3-Hydroxycinnamic acid, (19) 4-Hydroxycinnamic acid, (20) Eugenol (4-allyl-2methoxyphenol). (B) Effect of curcumin and its analogues on TNF-induced DNA**binding of NF-\kappaB.** U937 cells (2× 10⁶/ml) were incubated at 37°C with curcumin (50 μ M) for 2 h, and then treated with TNF (0.1 nM) for 30 min. Nuclear extracts were prepared and assayed for NF-KB by EMSA as described under "Materials and Methods". (C) Effect of curcumin and its analogues on NF-kB-dependent reporter gene expression. A293 cells were transiently transfected with the NF-kB-containing plasmid linked to the SEAP reporter gene. After 18 h of transfection, the medium was changed and the cells were exposed to curcumin analogues $(10 \,\mu\text{M})$ for 2 h and then to 1 nM TNF for 24 h. Supernatants were then collected and assayed for SEAP activity as described in "Materials and Methods". Results are expressed as fold activity over the non-transfected controls; bars, SD. (D) Effect of curcumin on DNA binding in vitro. U937 cells were treated with 0.1 nM TNF at 37°C for 30 min, then prepared the nuclear extracts, treated with different concentration of curcumin and then assayed for NF-kB specific DNA binding by EMSA.

Fig. 2. Curcumin inhibits NF-kB-dependent reporter gene expression.

(A). Curcumin inhibits TNF-induced NF-κB reporter activity in a dose-dependent manner. Human embryonic 293 cells were transiently transfected with a plasmid

MOL 17400

containing NF-KB binding sites linked to the SEAP gene. After 18 h of transfection, the medium was changed and the cells exposed to the indicated concentrations of curcumin for 2 h and then incubated with 1 nM TNF for 24 h. Cell supernatants were then collected and assayed for SEAP activity as described in Materials and Methods. Results are expressed as fold activity over the non-transfected control; bars, s.d., standard deviation. (B) Curcumin inhibits NF-kB -dependent reporter gene expression induced by TNFR1, TNFR2, NIK, IKK and p65. Human embryonic 293 cells were transiently transfected with indicated plasmids along with a NF-kB-containing plasmid linked to the SEAP gene for 18 h. After a medium change, the cells were treated with 10 µM curcumin for 24 h. Where indicated, cells were exposed to 1 nM TNF for 24 h after 2 h preincubation with 10 µM curcumin. Supernatants were collected and assayed for secreted alkaline phosphatase (SEAP) activity as described in Materials and Methods. Results are expressed as fold activity over the non-transfected control; bars, s.d., standard deviation. (C) Curcumin inhibits TNF-induced COX-2 -dependent reporter gene expression. Human embryonic A293 cells were transiently transfected with COX-2 promoter driven luciferase-containing plasmid. After 18 h of transfection, the medium was changed and the cells exposed to curcumin for 2 h and then to 1 nM TNF. After 24 h in culture with TNF along with curcumin, cell supernatants were collected and assayed for luciferase activity as described in Materials and Methods. Results are expressed as % of the β -gal luciferase controls; bars, standard deviation. (D) Curcumin inhibits TNF-induced cell proliferative gene products COX-2, cyclin D1 and c-myc expression. U937 cells (2 x 10⁶/ml), either left untreated or pretreated with 50 µM curcumin for 2 h, and then were exposed to TNF (1

MOL 17400

nM) for different times. Whole-cell extracts were prepared, and 80 µg of the whole-cell lysate was analyzed by Western blot using antibodies against COX-2, cyclin D1 and c-myc.

(E) Curcumin inhibits TNF-induced expression of antiapoptotic gene products. U937 cells (2 x 10^{6} /ml), either left untreated or pretreated with 50 µM curcumin for 2 h, and then were exposed to TNF (1 nM) for different times. Whole-cell extracts were prepared, and 80 µg of the whole-cell lysate was analyzed by Western blot using antibodies against various indicated antiapoptotic gene products. (F) Curcumin inhibits TNF-induced expression of metastatic gene products. U937 cells (2 x 10^{6} /ml), either left untreated or pretreated with 50 µM curcumin for 2 h, and then were exposed to TNF (1 nM) for different times. Whole-cell extracts were prepared, and 80 µg of the whole-cell lysate was analyzed by Western blot using antibodies against MMP-9, ICAM-1 and VEGF. (G). Curcumin suppresses TNF-induced invasion activity. A. H1299 (2.5 x 10^{4} cells) were seeded to the top chamber of Matrigel invasion chamber overnight in the absence of serum, pretreated with indicated concentration of curcumin for 4 h, and thens were exposed to 1 nM TNF for 24 h in the presence of 1 % serum, and then subjected to invasion assay as described in Materials and Methods.

Fig. 3. Curcumin suppresses TNF-dependent NF-κB activation. (A) U937 cells (2 x 10^{6} /ml) were pre-incubated at 37°C for 2 h with the indicated concentrations of curcumin followed by 30-min incubation with 0.1 nM TNF. After these treatments, nuclear extracts were prepared and then assayed for NF-κB, as described in Materials and Methods. (B) U937 Cells were preincubated at 37°C with 50 µM curcumin for the indicated times and then tested for NF-κB activation after treatment with or without 0.1 nM TNF at 37°C for 30

min. After treatment, nuclear extracts were prepared and assayed for NF- κ B. (C) NF- κ B consists of p50 and p65 subunits, and its binding to DNA is specific. Nuclear extracts were prepared from untreated or TNF (0.1 nM)-treated U937 cells (2 x 10⁶/ml), incubated for 30 min with different antibodies or unlabeled NF- κ B oligo probes, and then assayed for NF- κ B by EMSA.

Fig. 4. (A) Effect of curcumin on TNF-induced degradation of IkBa U937 cells were incubated at 37°C with curcumin (50 µM) for 2 h and then treated with 0.1 nM TNF at 37°C for the indicated times and tested for IkBa in cytosolic fractions by Western blot analysis. Protein loading was evaluated by β -actin. (B) Curcumin inhibits TNF-induced **phosphorylation of IkBa**. U937 cells $(2 \times 10^{6}/\text{ml})$ were incubated first with curcumin (50 μ M) for 2 h and then treated with 100 μ g/ml ALLN for 1 h thereafter; cells were treated with TNF (0.1 nM) for the indicated times and analyzed by Western blotting using antibodies against phosphorylated IkBa. (C) Curcumin inhibits TNF-induced IKK activity. U937 cells (2 x 10^6 cells/ml) were treated with 50 μ M curcumin for the indicated time intervals and then activated with TNF (1 nM) for 15 min. (D) U937 cells (2 x 10^6 cells/ml) were treated with the indicated concentrations of curcumin for 2 h and then activated with TNF (1 nM) for 15 min. Whole cell extracts (WCE) were prepared, and 200 μ g of the protein was immunoprecipitated with antibodies against IKK- α and IKK- β . Thereafter an immune complex kinase assay was performed as described in Materials and Methods. To examine the effect of curcumin on the level of expression of IKK proteins, 30 µg of WCE protein was run on a 7.5% SDS-PAGE, electrotransferred, and immunoblotted

MOL 17400

with the indicated antibodies. (E). Direct effect of curcumin on the activation of IKK induced by TNF. Whole-cell extracts were prepared from 1 nM TNF-treated U-937 cells and 1 mg of the protein was immunoprecipitated with IKK- α antibody. The immunocomplex kinase assay was then performed in the absence or presence of the indicated concentration of curcumin.

Fig. 5. (A) Curcumin inhibits TNF-induced nuclear translocation of p65 expression.

U937 cells (2 x 10^{6} /ml) were incubated first with curcumin (50 μ M) for 2 h, and then cells were treated with 0.1 nM TNF for the indicated times, and nuclear extracts were prepared and analyzed by Western blotting using antibodies against p65. (**B**) **Curcumin inhibits**

TNF-induced nuclear translocation of p65. U937 cells (1 x 10^{6} /ml) were either left untreated or were pretreated for 2 h with 50 µM curcumin at 37°C and then treated with 1 nM TNF. After cytospin, immunocytochemistry was performed as described in Materials and Methods. (C) Curcumin inhibits TNF-induced phosphorylation of p65. U937 cells (2 x 10^{6} /ml) were incubated first with curcumin (50 µM) for 2 h and then treated with 100 µg/ml ALLN for 1 h thereafter; cells were treated with 0.1 nM TNF for the indicated times and analyzed by Western blotting using antibodies against the phosphorylated form of p65.

Fig. 6. (**A**) **Effect of curcumin on TNF-induced acetylation of p65.** U-937 cells were treated with 50 μM curcumin for 2 h and then exposed to 1 nM TNF. Whole-cell extracts were prepared, immunoprecipitated with anti-p65 antibody, and subjected to Western blot analysis using anti-acetyl-lysine antibody. The same blots were reprobed with anti-p65 antibody. (**B**) **Effect of curcumin on TNF-induced Akt activation.** Cells were incubated

Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.

MOL 17400

with 50 μ M curcumin for 2 h, and then treated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared and analyzed by Western blot analysis using antiphospho-specific Akt. The same membrane was reblotted with anti-Akt antibody.


Fig. 7. (A) Dithiothreitol (DTT) reverses curcumin-mediated suppression of TNF-


induced NF-\kappaB. U937 cells (2x10⁶) were co-treated with indicated concentrations of DTT and curcumin (50 μ M) for 4 h and then treated with TNF (0.1 nM) for 30 min. Nuclear extracts were then prepared and examined by EMSA.

(B) Glutathione reverses curcumin-mediated suppression of TNF-induced NF-kB.


U937 cells $(2x10^6)$ were co-treated with indicated concentrations of glutathione and curcumin (50 μ M) for 4 h and then treated with TNF (0.1 nM) for 30 min. Nuclear extracts were then prepared and examined by EMSA.

Curcumin analogues







4-Hydroxybenzylacetone [11]




4-Hydroxybenzophenone [12]







Caffeic acid (3,4-Dihydroxycinnamic acid) [3]



3,4-Methylenedioxy cinnamic acid [4]




3,4-Dimethoxy cinnamic acid [5]




Cinnamic acid [6]




(CH₃)₂N




1,5-Bis(4-dimethylaminophenyl)-1,4-pentadien-3-one [13]




4-Hydroxyphenethyl alcohol [14]




4-Hydroxyphenyl pyruvic acid [15]




3,4-Dihydroxyhydrocinnamic acid [16]




Zingerone [7]




Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final persion may differ from this version. 4-(3,4-Methylenedioxyphenyl)-2-butanone [8]






2-Hydroxycinnamic acid [17]



3-Hydroxycinnamic acid [18]




4-Hydrocinnamic acid [19]

H₃CO.


HO









1 5 0.7 3 1.8 2.5 1.7 2.5 1.4 2 2.2 2.4 4 Fold





1 6 0.7 3.5 2.8 3.5 2.9 4.5 4.4 4.6 1.5 Fold


Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.




C.

D. $\frac{\text{TNF}}{0 \quad 0 \quad 5 \quad 10 \quad 25 \quad 50 \quad 100 \quad 150 \quad 200 \quad 300} \quad \text{Curcumin (μM$)}$












F2




Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.


Α.


F2

D.

Ε.








Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.




F2

G.

F.








5.8 1.4 Fold 7 7 8 1

B.

Α.









⊲NF-κB


Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.


C.

Fold 75 4.2 1.2 1













C.












Β.



A.




B.



Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.

Α.


- - + + + + + + + + + TNF - + - - + + + + + - - - Curcumin - - + - - 50 100 250 50 100 250 DTT (μM)




⊲NF-κ**B**

1 0.8 1 7.1 1.8 4.8 4.8 4.9 7.1 7.1 7.1 Fold

B.





■NF-κ**B**

Molecular Pharmacology Fast Forward. Published on October 11, 2005 as DOI: 10.1124/mol.105.017400 This article has not been copyedited and formatted. The final version may differ from this version.

1 0.8 1 7 1.8 6.2 7 7.7 7.1 7.1 6.7 Fold